ClinicalTrials.gg
RecruitingNCT07730515Updated Jul 29, 2026

Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma

A Phase 1/2 interventional study of XNW5004 combined with CHOP (incremental) and XNW5004 combined with CHOEP (incremental) in Non-hodgkin Lymphoma and Peripheral T-cell Lymphoma, sponsored by Evopoint Biosciences Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Primary conditionLymphoma, T-Cell, PeripheralRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, T-Cell, Peripheral
Why
  1. The study's listed conditions name Lymphoma, T-Cell, Peripheral, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Evopoint Biosciences Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Aug 2025, registered Jul 2026).
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
176
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cyclophosphamide in Lymphoma, T-Cell, Peripheral — 4 open to participants now, 6 under way, 1 of them phase 3. Cyclophosphamide · Lymphoma, T-Cell, Peripheral.

Planned enrollment
2nd of 15
176 · median 49
Started
2025
the only one that year
Phase 1/2
Only one
of the 15
Registered
14th of 15
by date
Lead sponsor
1 of 15
Evopoint Biosciences Inc.

Among the 15 studies testing cyclophosphamide in Lymphoma, T-Cell, Peripheral, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is the only one in phase 1/2, and was the 14th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

4 of the 15 studies testing cyclophosphamide in Lymphoma, T-Cell, Peripheral are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cyclophosphamide in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.

03

Conditions studied

  • Non-hodgkin Lymphoma
  • Peripheral T-cell Lymphoma

Browse trials for

Keywords

  • EZH2 inhibitor
  • XNW5004
04

In context

Lymphoma, T-Cell, Peripheral Reclassified

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

This study's planned enrollment of 176 is above the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.

Browse Lymphoma, T-Cell, Peripheral studies →

Lead sponsor

Evopoint Biosciences Inc. is the lead sponsor of 21 studies on the registry; 12 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Lymphoma, T-Cell, Peripheral, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years (inclusive); both genders are eligible.
  • confirmed peripheral T-cell lymphoma (PTCL).
  • No prior systemic anti-PTCL therapy.
  • At least one as the basis for evaluation: nodal lesions with a long diameter > 1.5 cm; extranodal lesions with a long diameter > 1.0 cm.
  • of at least 12 weeks.
  • performance status score of 0-1.
  • Vital organ function reserves meet the following requirements:
  • Hematopoietic function:
  • White blood cell count >= 3.5 x 10\^9/L (no G-CSF administration within 1 week before the screening blood test, and no long-acting leukocyte-elevating agent administration within 2 weeks)
  • count >= 75 x 10\^9/L (no platelet transfusion or TPO receptor agonist administration within 1 week before the screening blood test)
  • >= 80 g/L (no red blood cell transfusion or EPO administration within 1 week before the screening blood test)
  • Hepatic function: serum total \<= 1.5 x (\<= 3 x ULN for Gilbert's syndrome), and and AST \<= 2.5 x ULN; for subjects with liver infiltration, ALT/AST \<= 5 x ULN; for subjects with liver and/or bone infiltration, alkaline phosphatase \<= 5 x ULN
  • Renal function: serum creatinine \<= 1.5 x ULN or estimated >= 60 mL/min according to the Cockcroft-Gault formula
  • (LVEF) >= 50%
  • (INR) \<= 1.5 x ULN, or prothrombin time (PT) and activated partial thromboplastin time (APTT) \<= 1.5 x ULN
  • Women of must have a negative serum pregnancy test before entering this study and agree to use effective from the start of the study until at least 6 months after the last dose of the drug. Female subjects who are not capable of childbearing must have been naturally amenorrheic for at least 12 months and be confirmed by a specialist physician as having no reproductive function based on female hormone testing; or have undergone bilateral oophorectomy, hysterectomy, or tubal ligation at least 6 weeks prior to screening. Male subjects must agree to use adequate contraceptive measures from the start of the study until at least 6 months after the last dose of the investigational drug, and must not donate sperm.
  • Provide a signed and dated written form prior to undergoing study-specific procedures, and be able to comply with clinical visits and study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any anti-tumor therapy, including but not limited to: chemotherapy, immunotherapy, radiotherapy, targeted therapy, anti-tumor traditional Chinese medicine, or anti-tumor drugs.
  • Subjects with known to the investigational drug or its active ingredients or .
  • Subjects who have undergone major surgery within 4 weeks prior to the first dose of the investigational drug, or who plan to undergo major surgery during the study period (except for procedures such as puncture or lymph node ).
  • Prior or planned hematopoietic stem cell transplantation or solid organ transplantation.
  • Receipt of hormones for anti-tumor purposes (daily dose > 20 mg prednisone or equivalent dose of other glucocorticoids) within 7 days prior to the first dose of the investigational drug; or diseases requiring systemic treatment with steroid hormones (daily dose > 10 mg prednisone or equivalent dose of other glucocorticoids) or other drugs within 14 days prior to the first dose of the investigational drug. In the absence of active disease, inhaled or topical steroids and adrenal replacement therapy with a daily dose \<= 10 mg prednisone or equivalent dose of other glucocorticoids are permitted.
  • Subjects who have taken known moderate or strong inhibitors/inducers within 14 days prior to the first dose.
  • Receipt of (including attenuated live vaccine) within 28 days prior to dosing. Inactivated vaccines are permitted.
  • History of psychotropic substance abuse or drug addiction.
  • History of other within 3 years prior to enrollment that do not meet clinical cure criteria. The following are exceptions: basal cell carcinoma or squamous cell carcinoma of the skin that can be treated locally and has been cured, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma.
  • Mycosis fungoides, Sezary syndrome, and primary cutaneous T-cell lymphoma.
  • Presence of central nervous system involvement.
  • Presence of testicular or breast involvement.
  • Prior or current hemophagocytic syndrome.
  • Prior or current immune thrombocytopenia, autoimmune hemolytic anemia, aplastic anemia, or other primary or secondary hematological diseases that may affect bone marrow function other than the primary malignancy.
  • Prior or current acute myeloid leukemia (AML).
  • Prior or current T-cell lymphoblastic lymphoma (T-LBL) or T-cell lymphoblastic leukemia (T-ALL).
  • History of any myeloid malignancy, including myelodysplastic syndrome (MDS), or abnormal laboratory markers associated with MDS or myeloproliferative neoplasm (MPN).
  • Prior or concomitant central nervous system disorders, including but not limited to: epilepsy, paralysis, stroke, severe brain injury, Alzheimer's disease, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, etc.
  • Impaired cardiac function or cardiac disease, including any of the following:
  • Acute myocardial infarction within 12 months prior to the first dose
  • Unstable angina pectoris
  • Congestive heart failure ( functional class III or IV)
  • Uncorrected serious arrhythmia, hypertension >= 150/100 mmHg
  • Prolonged (defined as > 450 ms for males and > 470 ms for females, by Fredericia's formula)
  • Prior history of other major cardiovascular diseases (e.g., valve replacement, coronary artery bypass grafting, etc.)
  • Tumor invasion of surrounding vital organs and blood vessels (e.g., heart and pericardium, trachea, esophagus, aorta, superior vena cava, etc.) with risk of bleeding, or risk of tracheoesophageal fistula or esophagopleural fistula.
  • Subjects with clinically symptomatic pleural effusion, ascites, or pericardial effusion that is poorly controlled despite repeated treatment.
  • Active severe systemic infection: a of at least 2 weeks is required after completion of antifungal therapy (whether administered intravenously or orally); a washout period of at least 1 week is required after completion of other intravenous anti-infective therapy; other oral anti-infective therapies must be discontinued before the first dose of the investigational drug.
  • Active tuberculosis under treatment.
  • -positive or syphilis (Anti-TP) positive subjects (subjects with negative syphilis non-specific antibody test results and judged by the investigator to have been cured of syphilis are not excluded).
  • positive with HBV-DNA copy number above the lower limit of normal detection, or HBcAb positive with HBV-DNA copy number above the lower limit of normal detection; antibody positive with HCV-RNA copy number above the lower limit of normal detection.
  • Subjects who are unable to swallow, or have active gastrointestinal inflammation, chronic diarrhea, known diverticular disease, or a history of gastrectomy or gastric banding that may affect drug absorption. However, gastroesophageal reflux treated with proton pump inhibitors is permitted (if there is no potential for drug interaction).
  • Known hemorrhagic diathesis such as von Willebrand disease or hemophilia.
  • Females who are pregnant or breastfeeding.
  • Subjects who may not be able to complete the study for other reasons or whom the investigator considers should not be enrolled.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    Ib stage,Cohort1

    Phase of dose escalation for the XNW5004 tablet in combination with CHOP regimen.

    Drug: XNW5004 combined with CHOP (incremental)

  • Experimental
    Ib stage,Cohort2

    Phase of dose escalation for the XNW5004 tablet in combination with CHOEP regimen

    Drug: XNW5004 combined with CHOEP (incremental)

  • Experimental
    Phase II, dose expansion stage,CHOP

    XNW5004 combined with CHOP

    Drug: XNW5004 combined with CHOP (extended)

  • Experimental
    Phase II, dose expansion stage,CHOEP

    XNW5004 combined with CHOEP

    Drug: XNW5004 combined with CHOEP (extended)

Interventions

  • DrugXNW5004 combined with CHOP (incremental)

    Drug page: Cyclophosphamide

    The XNW5004 protocol has preset four dosage groups: 400mg, 800mg, 1200mg and 1600mg, administered twice daily (BID). The CHOP regimen is administered at a fixed dose, for a total of 6 cycles. After completing the combined treatment and without disease progression, the subjects will continue to receive XNW5004 at 1200mg BID for maintenance therapy.

    Also known as: cyclophosphamide, doxorubicin, vincristine, prednisone acetate tablet, XNW5004

  • DrugXNW5004 combined with CHOEP (incremental)

    Drug page: XNW5004

    It is expected to conduct dose escalation studies for XNW5004 in combination with CHOEP using 1-3 dose groups. The CHOEP regimen will be administered at a fixed dose for a total of 6 cycles. After completing the combined treatment and without disease progression, the subjects will continue to receive XNW5004 at 1200mg BID for maintenance therapy.

    Also known as: XNW5004, cyclophosphamide, doxorubicin, vincristine, prednisone acetate tablet, etoposide

  • DrugXNW5004 combined with CHOP (extended)

    Drug page: XNW5004

    Those who received the combination treatment of XNW5004 and CHOP, and who did not experience disease progression after the combined treatment, will continue to receive maintenance treatment with XNW5004 at a dose of 1200mg twice daily.

    Also known as: XNW5004, cyclophosphamide, doxorubicin, vincristine, prednisone acetate tablet

  • DrugXNW5004 combined with CHOEP (extended)

    Drug page: Cyclophosphamide

    Those who received the combination treatment of XNW5004 and CHOEP, and who did not experience disease progression after the combined treatment, will continue to receive maintenance treatment with XNW5004 at a dose of 1200mg twice daily.

    Also known as: cyclophosphamide, doxorubicin, vincristine, prednisone acetate tablet, etoposide

07

What researchers measure

Primary outcomes

  1. Ib/II:Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability].

    Incidence and severity of adverse events that are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: through study completion, an average of 1 year

  2. II:Objective response rate (ORR)

    ORR is defined as the proportion of subjects who have a confirmed CR or a PR per lugano2014 assessed by Investigator.

    Time frame: 36 months

  3. Ib:Maximum tolerated dose (MTD) and/or the recommended Part 2 dose

    To determine the maximum tolerated dose (MTD) and the recommended Part 2 dose with XNW5004.

    Time frame: The first 21-day cycle of therapy

Secondary outcomes

  1. Ib/II:The maximum (peak) blood drug concentration (Cmax) is XNW5004

    Collect blood samples at the specified intervals to determine the Cmax.

    Time frame: through study completion, an average of 1 year

  2. Ib/II:XNW5004 Peak Time (Tmax)

    Collect blood samples at the specified intervals to determine the Tmax.

    Time frame: through study completion, an average of 1 year

  3. Ib/II:The area under the blood drug concentration-time curve of XNW5004 (AUC)

    Collect blood samples at specified intervals to determine AUC

    Time frame: through study completion, an average of 1 year

  4. Ib/II:The maximum (peak) blood drug concentration in the steady state (Css,max)

    Collect blood samples at specified intervals to determine Css,max

    Time frame: through study completion, an average of 1 year

  5. Ib/II:XNW5004 Steady-state Baseline Concentration (Css, min)

    Collect blood samples at specified intervals to determine Css, min

    Time frame: through study completion, an average of 1 year

  6. Ib/II:The area under the blood drug concentration-time curve (AUCss) under steady-state conditions of XNW5004

    Collect blood samples at specified intervals to determine AUCss

    Time frame: through study completion, an average of 1 year

  7. Ib/II:XNW5004 Elimination Half-Life (T1/2)

    Collect blood samples at specified intervals to determine T1/2

    Time frame: through study completion, an average of 1 year

  8. Ib/II:Pharmacodynamic indicators, the relative change of H3K27me3 (trimethylation of lysine at position 27 of histone H3) compared to the baseline of histone H3

    Collect blood samples at the specified time to determine the relative changes of H3K27me3 (trimethylation of lysine at position 27 of histone H3) compared to the baseline.

    Time frame: through study completion, an average of 1 year

  9. Ib/II:Objective Response Rate (ORR)

    ORR is defined as the Lugano 2014 assessment, representing the proportion of subjects who were diagnosed with CR or PR.

    Time frame: 36 months

  10. Ib/II:Disease Control Rate (DCR)

    Rate of complete response \[CR\], partial response \[PR\], and stable disease per lugano2014 assessed by Investigator.

    Time frame: 36 months

  11. Ib/II:Duration of response (DOR)

    Duration of response (DOR) per lugano2014 assessed by Investigator.

    Time frame: 36 months

  12. Ib/II:Progression free survival (PFS)

    Progression free survival (PFS) per lugano2014 assessed by Investigator

    Time frame: 36 months

  13. Ib/II:Overall Survival (OS)

    The period from when the patient begins receiving treatment until the patient dies for any reason

    Time frame: 36 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2028, 37 months after the start.

Of 31 phase 1/2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 65. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 28, 2026
StartActual
Aug 15, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07730515
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Aug 15, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Linlin.li Li
Contact
linlin.li@evopointbio.com
18678888561

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · XNW5004

Start the discussion